Scilex Holding (NASDAQ:SCLX) Bolsa

SCILEX HOLDING CO

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Scilex Holding Co

<ul>
<li>Federal Reserve Governor Christopher Waller says he's "a big advocate of stablecoins"</li>
<li>Voicing his support for stablecoin acts like the GENIUS act and the STABLE act, he says he sees no need for the government to develop a coin of its own</li>
<li>"I prefer to let the private sector handle these problems," he told audiences at a NY Fed event</li>
</ul>
Federal Reserve Governor Christopher Waller said that he's a fan of stablecoins and believes they have a place in the payment system, but does not see the need for the government to adopt one of their own.&nbsp;
"I&#8217;ll say I&#8217;m a personal, big advocate of stablecoins. I have been saying this for over three-plus years now, about how this could bring competition, efficiency and speed into the payments system,&#8221; he told audience members at a conference held by the Federal Reserve Bank of New York on Friday, according to <a href="https://www.reuters.com/technology/feds-waller-stablecoins-bring-benefits-payment-system-2025-04-04/">Reuters</a>.&nbsp;
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
A stablecoin is a type of cryptocurrency that is designed to have a stable price. Their value is attached to that of another asset, like gold or a government-issued currency, in order to maintain a more consistent value. Originally designed to help bridge the gap between traditional finance and cryptocurrencies, there are currently around 200 globally distributed stablecoins on the market.&nbsp;&nbsp;
Recently, two stablecoin-oriented bills have been working their way through Congress. The Guiding and Establishing National Innovation for U.S. Stablecoins of 2025, or the <a href="https://www.congress.gov/bill/119th-congress/senate-bill/394/text/is">GENIUS Act of 2025</a>, and the Stablecoin Transparency and Accountability for a Better Ledger Economy Act of 2025, or the <a href="https://www.congress.gov/bill/119th-congress/house-bill/2392/text/ih?overview=closed&amp;format=xml">STABLE Act of 2025</a>, both seek to provide a comprehensive regulatory framework for stablecoins. The difference between the bills lies in their scope and approach, but the passing of either one would increase the chances of Congress passing a law certifying stablecoins as a global financial tool.&nbsp;
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
Thus far, stablecoin legislation has received bipartisan support. But Waller said Friday that he saw no need for the government to create its own stablecoin should either of the bills pass. "I prefer to let the private sector solve these problems,&#8221; Reuters quoted him as saying. &#8220;It&#8217;s not my job as an unelected bureaucrat to tell everybody how they should do things."
As for the concerns that tons of new stablecoins will flood the market should the legislation pass, Waller said watchers shouldn't worry. "I don't think… there's going to be 100 stablecoins circulating after the legislation happens." Though two companies, Tether and Codex, have already indicated that they will make moves to establish their own stablecoins in the US as soon as there are regulations firmly in place, according to the <a href="https://www.ft.com/content/1b3cccad-ad33-4dd9-b2b6-1514f80e39ad">Financial Times</a> and <a href="https://fortune.com/crypto/2025/04/04/codex-seed-round-dragonfly-coinbase-circle-15-8-million/">Fortune</a>.&nbsp;
Waller's stance on crypto aligns with President Donald Trump's, who promised last month to make the US "the crypto capital of the world."&nbsp;
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>

Personal Finance

Federal Reserve Governor Says He's A 'Big Advocate Of Stablecoins,' But Wants The Government To Steer Clear Of Own Crypto

MULN

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

HCWB

AMRN

Former House Speaker Nancy Pelosi (D-CA) blasted President Donald Trump over his tariff policy last week, warning that it could result in serious economic damage for American families. She also invoked Republican icon Ronald Reagan to drive home her point.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Trump Administration&#39;s flagrant ineptitude is tanking our economy in a self-inflicted disaster that leaves hardworking American families bearing the brunt of the pain. Make no mistake: President Trump&#39;s senseless tariffs will drive prices higher, drain retirement savings and…
&mdash; Nancy Pelosi (@SpeakerPelosi) <a href="https://twitter.com/SpeakerPelosi/status/1908238636346466795?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;President Trump&#8217;s senseless tariffs will drive prices higher, drain retirement savings and push us to the brink of recession,&#8221; Pelosi <a href="https://x.com/SpeakerPelosi/status/1908238636346466795">posted</a> on X just days after Trump&#8217;s so-called &#8220;Liberation Day.&#8221; She described the situation as a &#8220;self-inflicted disaster&#8221; and accused the Trump administration of <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">tanking the economy</a> through what she called &#8220;flagrant ineptitude.&#8221;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">Referencing Reagan</h2>
To reinforce her message, Pelosi <a href="https://www.benzinga.com/markets/25/03/44269552/ronald-reagan-warned-that-tariffs-destroy-prosperity-trump-is-doubling-them-anyway-and-now-us-tech-giants-like-apple-and-nvidia-are-bracing-for-impact">quoted Reagan</a>: &#8220;We should beware of the demagogues who are ready to declare a trade war against our friends – weakening our economy, our national security, and the entire free world – all while cynically waving the American flag.&#8221; She added, &#8220;President Reagan's words were true then and they're true today.&#8221;
She also urged Republicans in Congress to reconsider their support for Trump's trade agenda.
<h2 class="wp-block-heading">Medicaid Cuts and Tax Breaks for Billionaires</h2>
Just weeks earlier, <a href="https://www.benzinga.com/25/02/43612979/nancy-pelosi-says-extreme-maga-republicans-have-revealed-their-tax-scam-to-plunder-medicaid-for-giving-tax-cuts-to-billionaires">Pelosi took aim</a> at what she called a &#8220;tax scam&#8221; by &#8220;extreme MAGA Republicans&#8221; that she claims is designed to slash Medicaid in order to fund tax breaks for billionaires.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
&#8220;Extreme MAGA Republicans revealed their tax scam to raid Medicaid to give more tax cuts to billionaires,&#8221; she <a href="https://x.com/TeamPelosi/status/1889100925673054462">shared</a> on X. &#8220;But we can stop them! We&#8217;ve done it before — we saved Social Security in 2006, the Affordable Care Act in 2018 and we&#8217;ll stop them now to save the ACA, Medicare and Medicaid.&#8221;
Pelosi described Republican efforts in Congress as &#8220;unbearable for people on Medicare and Medicaid,&#8221; and called for public pressure to stop the cuts, urging &#8220;outside mobilization.&#8221;
The Trump administration&#8217;s agenda has been stalled in Congress because of internal Republican disagreements on how deep the cuts to Medicaid should go.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">Broader Context and Fallout</h2>
The debate over tariffs and spending cuts comes amid other major moves by the Trump administration. A temporary freeze on federal grants and loans has put $3 trillion in funding under review. Around the same time, the <a href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected">Medicaid website experienced an outage</a>, which the White House blamed on a technical issue.
The Department of Government Efficiency, headed by Elon Musk, has also begun auditing the Centers for Medicare and Medicaid Services, with Musk claiming there is &#8220;big money fraud&#8221; in the system. The agency is under pressure to cut at least $1 trillion in federal spending.
<h2 class="wp-block-heading">Pelosi&#8217;s Market Losses</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wow. Nancy Pelosi has now lost $12M in the stock market in the last two days. Down another $4.5M today. <a href="https://t.co/v4dmOwI8FO">pic.twitter.com/v4dmOwI8FO</a>
&mdash; Quiver Quantitative (@QuiverQuant) <a href="https://twitter.com/QuiverQuant/status/1908210434005504178?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As the policy and tariff debates play out, Pelosi&#8217;s personal finances are also drawing attention. According to <a href="https://x.com/QuiverQuant/status/1908210434005504178">Quiver Quantitative</a>, she has lost $12 million in the stock market over just two days, including a $4.5 million drop on April 4 alone.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

News

'Trump's Tariffs Will Drain Retirement Savings, Push Us To The Brink Of Recession,' Says Nancy Pelosi While Quoting Ronald Reagan

You may want that new car. The smell, the shine, the 0% financing—what's not to love?
But Dave Ramsey just reminded everyone why that shiny $72,000 BMW might actually be torching your financial future. In a <a href="https://www.facebook.com/share/r/16FzUzF3Aa/?mibextid=wwXIfr">viral Facebook post</a>, he dropped a meme featuring Adam Sandler green-screened into a car dealership, shaking his head, saying "No, no, no, don't say that," before punching a wall in frustration. The caption?
"When you're trading in your $72K BMW and the dealer offers you $17K but you still owe $49K on it."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
And Ramsey didn't stop there. He followed it up with a caption that hits harder than a monthly payment:
"That $72,000 BMW isn't just costing you a car payment. It's costing you your future."
He's not exaggerating. <a href="https://www.experian.com/blogs/ask-experian/average-car-loan-interest-rates-by-credit-score/">According to Experian</a>, the average new car loan now clocks in at $40,927, with monthly payments pushing $734 for 68.4 months. Meanwhile, car values plummet the second you drive off the lot.&nbsp;
"Let me break it down: Open your car window on the way to work once a week and toss out a $100 bill. That's what driving a new car really costs you."
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
He's not just talking about luxury vehicles, either. Even a "reasonable" $28,000 new car will lose around $17,000 in value over four years. That's about $100 a week in pure depreciation—money that vanishes whether you're financing at 7% or zero.
Ramsey's take on 0% interest? Not impressed."Even 0% interest isn't a deal. It's a distraction from the $17K you just lost in depreciation. You didn't get a car. You got taken."
Here's his rule: "No, you can't afford a new car <a href="https://www.benzinga.com/25/03/44389799/why-dave-ramsey-says-your-typical-millionaire-may-look-just-like-your-next-door-neighbor">unless you are a millionaire</a> and can, therefore, afford to lose thousands of dollars, all in the name of the neat new-car smell."
He's not saying you'll never own a new car. But if dropping tens of thousands without blinking isn't an option, you're not ready for that kind of luxury.&nbsp;
"Until you have <a href="https://www.benzinga.com/24/11/42122576/dave-ramsey-guarantees-if-you-have-a-car-payment-you-will-be-broke-your-whole-life-heres-how-he-says-you-can-become-rich">so much money you can lose big bucks</a> and not notice, you can't afford the luxury."
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Want to know what most millionaires drive? It's not a brand-new German badge with 48 payments attached.
"Most millionaires drive two-year-old used cars with no payments—not because they're too cheap to buy new, but because they know how money works."
And that's the real lesson. You might think you're buying freedom, style, status—but if you're not careful, you're buying debt, depreciation, and regret.
So before you fall for the 0% APR pitch, remember what Ramsey said. You didn't get a deal. You got taken.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>

Dave Ramsey Says If You Want To Know What Driving A New Car Really Costs, 'Open Your Car Window Once A Week And Toss Out A $100 Bill'

BofA Securities analyst Craig Siegenthaler downgraded Cboe Global Markets Inc. (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Buy to Neutral, lowering the price <a href="https://www.benzinga.com/quote/CBOE/analyst-ratings" target="_blank" rel="noreferrer noopener">target to $227 from $260</a>.
The analyst noted that while the broader diversified financials sector has declined 10% year-to-date amid the growing tariff dispute, CBOE Global Markets has stood out by delivering a 5% return —outperforming its peers by about 15%.
This strong performance, according to Siegenthaler, is largely attributed to CBOE&#8217;s defensive business model, which tends to benefit during periods of heightened market volatility and increased trading volumes.
However, despite the solid year-to-date gains, the analyst expressed caution going forward.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44738776/versace-goes-prada-capris-big-exit-sparks-fashion-power-shift" rel="noreferrer noopener">Versace Goes Prada: Capri&#8217;s Big Exit Sparks Fashion Power Shift</a>
The stock's recent outperformance has led to a &#8220;higher relative valuation&#8221; compared to peers.
Siegenthaler pointed out that CBOE&#8217;s next 12 months, or NTM price-to-earnings ratio, has increased by 2% so far this year, while the average PE multiple for the broader diversified financials sector has dropped by 13%. As a result, CBOE now appears about 15% more expensive compared to its peers on a relative valuation basis.
The analyst also pointed to potential deceleration in trading volumes during the second half of 2025, which could weigh on future performance.
Siegenthaler writes that the first half of 2025 will likely mark the cyclical peak for exchange volumes, with a significant decline expected in the second half.
The analyst projects a 6% drop in volumes from the first to the second half of the year, and only a 7% year-over-year increase in total options volume for 2H25.
The analyst is especially concerned about the retail trading segment, where participation may fall due to poor investor performance so far this year.
Siegenthaler lowered earnings estimates for the second half of 2025 and the following years.
The new projections are $4.60 for the second half of 2025, $9.89 for 2026, and $11.37 for 2027 — down from previous estimates of $5.07, $11.16, and $12.99, respectively.
CBOE Price Action: CBOE shares closed Thursday up 2.05% to $210.02.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44731044/jim-cramer-says-pre-market-slide-driven-by-profit-takers-shorts-are-trying-to-figure-whether-to-operate-on-nvidia-avgo-aapl" target="_blank" rel="noreferrer noopener">Jim Cramer Says Pre-Market Slide Driven By Profit-Takers: ‘Shorts Are Trying To Figure Whether To Operate On Nvidia, AVGO, AAPL'</a></li>
</ul>

Options

Markets

Analyst Ratings

Movers

Trading Ideas

General

CBOE

CBOE Loses Its Edge? Analyst Downgrades Stock On Valuation Worries, Volume Slowdown

Goldman Sachs analyst Mark Delaney upgraded BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from Neutral to Buy, <a target="_blank" href="https://www.benzinga.com/quote/BWA/analyst-ratings" rel="noreferrer noopener">with a price forecast of $34</a>.
Per Delaney, BorgWarner has a below-average level of U.S. imports, which means it faces relatively limited risk from ongoing or future tariffs.
In contrast to many Western suppliers that have struggled in China due to an unfavorable customer mix, BorgWarner stands out with a stronger positioning in the region.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44746593/goldman-sachs-hits-the-brakes-auto-tariffs-slumping-demand-may-shake-up-ford-tesla-rivian-lear-visteon" rel="noreferrer noopener">Goldman Sachs Hits The Brakes: Auto Tariffs &amp; Slumping Demand May Shake Up Ford, Tesla, Rivian, Lear &amp; Visteon</a>
Around 20% of the company's total revenue comes from China, and approximately 75% is tied to domestic Chinese original equipment manufacturers (OEMs). About 90% of its eProduct business in China is also linked to these domestic OEMs.
Delaney highlighted that BorgWarner's hybrid and internal combustion engine products are expected to have a longer runway, and the company's broad portfolio—which includes products for all powertrain types—positions it well to navigate evolving market trends.
The analyst also highlighted that BorgWarner has a number of upcoming product launches with domestic Chinese auto OEMs, further strengthening its foothold in this key market.
With higher content per vehicle opportunities in both hybrid and battery electric vehicles, BorgWarner is expected to benefit from the rising share of hybrid volumes in the near to medium term.
While its eProduct division is still operating at a loss, the analyst stated that ongoing restructuring efforts, coupled with long-term growth, will help the company move toward profitability.
Price Action: BWA shares closed lower by 4.54% to $25.67 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns" target="_blank" rel="noreferrer noopener">China's Growth Outlook Dims As Trump's 125% Tariffs Put Millions Of Jobs At Risk, Goldman Warns</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Analyst Color

Equities

Price Target

BorgWarner Has Hidden Value In A Hybrid-Heavy Future: Analyst

YCBD

cbdMD Shareholders Approve Automatic Conversion Of Series A Preferred Stock And Other Results From Annual Meeting

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $132.56, a high estimate of $153.00, and a low estimate of $110.00. Observing a downward trend, the current average is 4.78% lower than the prior average price target of $139.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322499_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Crocs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$138.00 &#x7C; 
&#x7C;Laura Champine &#x7C;Loop Capital &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $132.00&#x7C;$122.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $122.00&#x7C;$125.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $153.00&#x7C;$144.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $150.00&#x7C;$180.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$155.00 &#x7C; 
&#x7C;Ashley Owens &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Crocs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crocs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Crocs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Crocs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CROX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crocs analyst ratings.</a>
<h2>Delving into Crocs's Background</h2>
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
<h3>Breaking Down Crocs's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Crocs displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.09%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Crocs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 37.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Crocs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 20.72%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Crocs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CROX

Assessing Crocs: Insights From 9 Financial Analysts

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $258.75, a high estimate of $265.00, and a low estimate of $240.00. Marking an increase of 0.49%, the current average surpasses the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322492_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Turkaly &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Jacob Johnson &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $265.00&#x7C;$260.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Steris's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Steris showcased positive performance, achieving a revenue growth rate of 5.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin is impressive, surpassing industry averages. With a net margin of 12.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Steris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.71%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Steris Stock

Across the recent three months, 7 analysts have shared their insights on Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Skechers USA, presenting an average target of $77.0, a high estimate of $90.00, and a low estimate of $62.00. Highlighting a 4.26% decrease, the current average has fallen from the previous average price target of $80.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322485_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Skechers USA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $62.00&#x7C;$80.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$76.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $77.00&#x7C;$80.00 &#x7C; 
&#x7C;Rick Patel &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $75.00&#x7C;$80.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $80.00&#x7C;$83.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $90.00&#x7C;$92.00 &#x7C; 
&#x7C;JESALYN Wong &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $85.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skechers USA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Skechers USA compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Skechers USA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Skechers USA's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SKX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skechers USA analyst ratings.</a>
<h2>All You Need to Know About Skechers USA</h2>
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
<h3>Understanding the Numbers: Skechers USA's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Skechers USA's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 12.82%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Skechers USA's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Skechers USA's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Skechers USA's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.45, Skechers USA adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Skechers USA Through 7 Analysts

21 analysts have expressed a variety of opinions on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for GE Vernova, presenting an average target of $430.57, a high estimate of $500.00, and a low estimate of $370.00. Marking an increase of 3.69%, the current average surpasses the previous average price target of $415.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322476_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of GE Vernova among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $425.00&#x7C;$436.00 &#x7C; 
&#x7C;Charles Minervino &#x7C;Susquehanna &#x7C;Announces &#x7C;Positive &#x7C; $370.00&#x7C;- &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $413.00&#x7C;$391.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $445.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $380.00&#x7C;- &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $420.00&#x7C;$471.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $427.00&#x7C;$487.00 &#x7C; 
&#x7C;Ben Kallo &#x7C;Baird &#x7C;Announces &#x7C;Outperform &#x7C; $448.00&#x7C;- &#x7C; 
&#x7C;Martin Malloy &#x7C;Johnson Rice &#x7C;Announces &#x7C;Buy &#x7C; $425.00&#x7C;- &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $453.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Neutral &#x7C; $380.00&#x7C;$380.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $500.00&#x7C;$446.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $470.00&#x7C;$420.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $471.00&#x7C;$420.00 &#x7C; 
&#x7C;Andrew Kaplowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $437.00&#x7C;$361.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $487.00&#x7C;$420.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $436.00&#x7C;$374.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $446.00&#x7C;$400.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $420.00&#x7C;$400.00 &#x7C; 
&#x7C;Andrew Obin &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $415.00&#x7C;$380.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $374.00&#x7C;$367.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GE Vernova. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GE Vernova compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for GE Vernova's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GE Vernova's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GE Vernova analyst ratings.</a>
<h2>Delving into GE Vernova's Background</h2>
GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.
<h3>A Deep Dive into GE Vernova's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, GE Vernova showcased positive performance, achieving a revenue growth rate of 5.11% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: GE Vernova's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): GE Vernova's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): GE Vernova's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GE Vernova's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying GE Vernova: Insights From 21 Analyst Reviews

5 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.6, a high estimate of $150.00, and a low estimate of $129.00. Observing a downward trend, the current average is 0.83% lower than the prior average price target of $143.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322469_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Addus HomeCare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $150.00&#x7C;$150.00 &#x7C; 
&#x7C;Scott Fidel &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C; 
&#x7C;Tao Qiu &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $142.00&#x7C;$153.00 &#x7C; 
&#x7C;Ari Wald &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $150.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>A Deep Dive into Addus HomeCare's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

What Analysts Are Saying About Addus HomeCare Stock

In the current market session, Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) stock price is at $164.31, after a 3.75% decrease. However, over the past month, the company's stock went up by 2.04%, and in the past year, by 48.85%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_0.png" alt="Past Year Chart" />

<h3>A Look at Interactive Brokers Group P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.84 in the Capital Markets industry, Interactive Brokers Group Inc. has a higher P/E ratio of 24.63. Shareholders might be inclined to think that Interactive Brokers Group Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

IBKR

P/E Ratio Insights for Interactive Brokers Group

7 analysts have expressed a variety of opinions on Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dana and provided 12-month price targets. The average target is $18.71, accompanied by a high estimate of $23.00 and a low estimate of $16.00. This current average has increased by 25.91% from the previous average price target of $14.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322459_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Dana by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;Tom Narayan &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $16.00&#x7C;$13.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $23.00&#x7C;$18.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $20.00&#x7C;$14.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $20.00&#x7C;$18.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $16.00&#x7C;$10.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $18.00&#x7C;$11.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dana. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dana analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dana</h2>
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
<h3>Breaking Down Dana's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Dana's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.38%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Dana's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dana's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.69%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.04%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.19, Dana faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Dana In The Eyes Of 7 Experts

BofA Securities analyst Robert F. Ohmes reiterated a <a target="_blank" href="https://www.benzinga.com/quote/WMT/analyst-ratings" rel="noreferrer noopener">Buy rating</a> on the shares of Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a price forecast of $120.00.
At the Investment Community Meeting in Dallas, the company <a target="_blank" href="https://www.benzinga.com/news/guidance/25/04/44711688/walmart-maintains-steady-growth-forecast-despite-tariffs" rel="noreferrer noopener">reiterated its full-year fiscal 2026 guidance</a>, initially shared during its fourth-quarter results in February.
While the sales outlook for the first quarter remains intact, Walmart has adjusted its EBIT growth projection for the period to reflect a wider range.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession" rel="noreferrer noopener">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
This revision comes amid a weaker product mix early in the quarter, particularly in general merchandise, although trends improved as the quarter progressed.
Additionally, the company is accounting for roughly $200 million in increased casualty-related costs and aims to preserve the ability to adjust pricing strategies in response to potential tariff impacts, which could support accelerated market share growth, said the analyst.
The analyst opined that despite ongoing ambiguity surrounding the scale and rollout of new tariffs, WMT appears better equipped than many peers to manage potential fallout.
The retailer highlighted that more than two-thirds of its U.S. merchandise is sourced domestically. For the rest, China and Mexico represent its primary import partners.
Walmart's strong supplier network, pricing and automation systems, along with efficient inventory management, offer meaningful strategic advantages.
Early-stage growth engines are also beginning to take effect including improved profitability in e-commerce, expansion in digital advertising and Marketplace, pharmacy delivery services, continued momentum in India through Flipkart, and gains at Sam's Club in both the U.S. and China.
Importantly, Walmart has not seen any notable anti-American sentiment across its international markets such as Walmex and Sam's Club China, further supporting its global positioning, noted the analyst.
Walmart's digital advertising revenue, which reached $4.4 billion in fiscal 2025, continues to grow despite economic headwinds. The company benefits from its large omni-channel footprint and increasing third-party marketplace participation.
Walmart's U.S. e-commerce segment turned profitable in the first quarter and is expected to remain profitable throughout the year.
With plans to reach 95% of U.S. households with same-day delivery and expand ultra-fast service, Walmart is also seeing strong gains from digital ads, fintech, automation, and membership programs, the analyst observed.
Price Action: WMT shares closed at $90.61 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44752453/bofa-turns-bullish-on-levi-strauss-with-strong-sales-and-low-china-exposure" target="_blank" rel="noreferrer noopener">Beyoncé Partnership, Strong Sales And Low China Exposure &#8211; Analyst Upgrades Levi Strauss To Buy</a></li>
</ul>
Image via Shutterstock

Reiteration

Walmart's Resilience Shines With Broad EBIT Forecast And Strong Growth Engines, Analyst Says

Biotech

ARGX

argenx SE Receives FDA Approval Of VYVGART Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy

Stocks staged a ferocious <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">rally</a> on Wednesday after President Donald Trump <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">reversed his ‘reciprocal' tariff policy</a> in response to plummeting markets and alarming bond market activity. 
While most countries are now exempt from the steepest import taxes, a 10% flat tariff remains in effect, and the tariffs on China have increased to 145%.
However, bond yields remain high, and stocks remain significantly below the all-time highs set in February, then fell again on Wednesday. Uncertainty continues to dominate the markets, and the risk of recession remains elevated.
It&#8217;s a great time to invest in dividends rather than capital gains. You can do that while still investing in tech stocks.
Here are five great tech stocks paying huge dividends.
Now, tech stocks aren't usually considered dividend payers, but there are a few with relatively sturdy payouts that investors can use to ride out this storm of uncertainty.
Today, we've compiled a list of four tech companies that have been raising their dividend payouts for at least 10 years. Each company has a dividend yield of at least 2%, a manageable payout rate, fair valuation, and a path to avoiding the most stringent tariffs currently being levied on China.
<h2 class="wp-block-heading">Avnet Inc.&nbsp;</h2>
Avnet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is a distributor of electronic components, including semiconductors, active and passive components, and other electromechanical parts, as well as design solutions and technical training. The company operates on every continent except Antarctica and is the largest chip distributor in Europe. Avnet's vast market reach should help it avoid the worst of the tariffs, and its valuation looks appealing following a rough showing in 2024.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcmcfLl3ZsWWHoGtw6seHhwWx95e7BOQptusKU6TvTEPpdOGv-20E1IHbachpysrHEXFOZ-p49dyxIX1H8kAmlmUaMxLnRWNPylAaClRBflOb2ddtsMzixfSGXQB60-0pBxMRyz?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
AVT shares are still underwater for 2025, but the stock trades at just 8.3 times forward earnings with a 0.18 Price-to-Sales (P/S) ratio. The dividend yield is currently 3.17%, and the payout rate is just 37%. Avnet has raised its annual dividend payout for 12 consecutive years and the 12% annualized growth rate over the last three years. The stock also has a 91.81 Value score from Benzinga Edge ratings, indicating a potentially undervalued company with a steady dividend.
<h2 class="wp-block-heading">Cisco Systems</h2>
Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) was the poster child of the dot-com bubble excess as its market cap rose above $500 billion by the turn of the millennium &#8211; a number it's never come close to reaching in the two-plus decades since. It's also been 25 years since the stock made a new all-time high over $77 per share (split-adjusted), although it came close in January this year when shares topped $66. Cisco will never dominate the tech landscape like it did during the dot-com years, but that doesn't mean it&#8217;s still an uninvestable company.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXe5fyzjG6ZB1JA5EMH2BVYHKTjMKC4q4JXlzZ3QaOcIdU6E-qoe_28yCwg-P_QCmTOtPBSwPtFXGwUhEgSqtP_SwP43WBoa5sUMgEQbFuuLowQNwHAyiQ_PRzm95261khbqW2tIXA?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Cisco currently yields 3.08% with a 12-year history of raising annual payouts. The dividend payout rate (DPR) is relatively high at 71%, but it&#8217;s still sustainable for a company that sells as much high-margin software as Cisco. The company posted more than $54 billion in sales in the last 12 months but still trades at just 14.6 times forward earnings.
With a focus on cybersecurity software over hardware, the company should be minimally impacted by the China tariffs. Analysts have a consensus Buy rating on the stock with an average price target of $63.43, including an $80 price target from Rosenblatt issued on February 13.
<h2 class="wp-block-heading">Qualcomm Inc.&nbsp;</h2>
Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is an example of a remarkable turnaround story in the market. Like Cisco, Qualcomm was a dot-com darling that rose to unsustainable heights during the bubble. Once the bubble popped in late 2000, Qualcomm shares plummeted and continued making new lows until the great financial crisis in November 2008. However, the stock rallied in the decade following the GFC and finally topped its dot-com bubble high in early 2019.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXc8M0O3izmpY0oKP52vW_Zmz8ljLYJGnyPblxrxL1wCSPo-UmEhwolQsyR5FlAdJehJ9CtZ7sYl7wEhwv_aha7Z66xu_7XO7ioj7rRMJejhIhXA_223nVSvzV5Jz4NyCJCRd6Kp?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Qualcomm's focus is on the development and licensing of wireless tech and chips for smartphones. Qualcomm products can be found in nearly every wireless device, and it does more than $40 billion in annual sales. QCOM shares also have a strong and steady dividend, yielding 2.73% with a manageable 36% payout rate. The company has a 22-year history of dividend increases, including a 7% annualized growth rate over the last three years. An affordable valuation backs the dividend; the stock trades at just 11.7 times forward earnings with impressive margins (26% profit margin in the most recent quarter).
Analysts are also bullish, with a $195 average price target indicating an upside potential of 35%. Benzinga Edge also gives Qualcomm a 91.82 Value score, the highest of today's selections.
<h2 class="wp-block-heading">CSG Systems International Inc.&nbsp;</h2>
Our smallest and least known company of the day might hold the most promise. CSG Systems International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) runs a software-as-a-service (SaaS) platform specializing in financial management and customer experience solutions. The company aims to help firms in the communications sector optimize their digital footprint while effectively managing revenue, licensing, and infrastructure. CSG Systems has been publicly traded for nearly 30 years but has just a $1.73 billion market cap and does $1.2 billion in annual sales. The company has solid margins (47% gross margin last quarter) and trades at just 12 times forward earnings.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfO3fvRSZ0Hspa09BnDdqv3XMwLZ__tfsZtMRv6E7cFzlwqla3nOJqjUrmNjceyHCfBqEhPmcDw2OWeps75UEMUXpE9neBnEOgRE-rwnrElVSw2TmcZhBezalvDUEZLlz3NJE8Axg?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Small and mid-cap companies are usually known for substantial dividends, but CSG Systems is an exception. The stock currently yields 2.13% and has a healthy 42% dividend payout rate. Despite its relatively small stature, CSGS has raised its annual payout for 12 consecutive years with a 6.3% annualized growth rate over the last three.
Unlike the rest of the market, CSGS shares are still positive year-to-date, including an impressive 17% gain over the last three months. Even during the worst of the tariff tantrum, the stock only dropped from $61 to $56 before rebounding back above $60 when the tariffs were withdrawn. This stability during the madness is likely why CSGS scored a 90.51 Momentum ranking from Benzinga Edge &#8211; shareholders barely noticed the disturbance!
<h2 class="wp-block-heading">3 New Trade Ideas For Monday</h2>
You can get special access to a deep-dive analysis into the upcoming week and events that could drive the markets and three trade ideas you can take advantage of as early as opening bell. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2">HERE</a> now to ensure you don't miss another round of trades.
Photo: Shutterstock

Opinion

Tech

CSCO

CSGS

QCOM

4 Tech Stocks With Surprisingly Strong Dividends

Retractable Technologies Reduces Its Workforce By ~ 7%. The Reduction Is Expected To Save An Estimated $1.6M In Annual Wages And Benefits, Or Approximately 7.8% Of Total Estimated Workforce Costs

Press Releases

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Contracts

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Health Care

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Dividends

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Legal

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

DECA

SCLX

SRNE

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Grace Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

Nutriband

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

D. Boral Capital

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Outside,Of,Logistics,Warehouse,With,Open,Door,,Delivery,Van,Loaded

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Interior,Of,A,Modern,Warehouse,Storage,Of,Retail,Shop,With

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Comments

Scilex Holding

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL